- Merck will buy Bio-Techne (TECH) for $73.00 per share in an all-cash deal making TECH a Merck unit pending shareholder and regulatory approvals; reciprocal breakup fees are disclosed.
- Bio-Techne approved cash retention bonuses for executives Kim Kelderman and Jim Hippel tied to a contemplated merger, specifying cash payments to retain them during the merger process.
- Baird lifted Bio-Techne (TECH) price target to $73 from $49, a $24 increase per share; no timeframe or analyst rationale provided.
TradingView
Key facts: Merck Buys Bio-Techne $73; Exec Bonuses; Baird Target $73
- Sources
- TradingView
- Markets
- Stocks
- Active symbols
- NASDAQ:TECH
- Language
- English
Merck will buy Bio-Techne (TECH) for $73.00 per share in an all-cash deal making TECH a Merck unit pending shareholder and regulatory approvals; reciprocal breakup fees are disclos